Quick View
| Metric | Current Period | Same Period Previous Year | YoY |
|---|---|---|---|
| Revenue | ¥856.5B | ¥818.3B | +4.7% |
| Operating Income | ¥60.8B | ¥78.8B | −22.9% |
| Ordinary Income | ¥67.1B | ¥76.0B | −11.8% |
| Net Income | ¥52.4B | ¥50.5B | +3.7% |
| ROE | 1.7% | 1.7% | - |
Executive Summary
In Q1 of the fiscal year ending March 2027, revenue increased, but higher SG&A expenses pressured earnings, resulting in declines at the operating and ordinary income levels. Meanwhile, extraordinary income, including gains on the sale of investment securities, boosted final profit. Revenue was ¥856.5B (+4.7% YoY), Operating Income was ¥60.8B (-22.9%), and Ordinary Income was ¥67.1B (-11.8%). Net Income attributable to owners of the parent was ¥52.0B (+6.0%), securing an increase in profit despite declines in Operating Income and Ordinary Income. The primary driver of revenue growth was the expansion of the Life Science Business (+61.5%), while the main factor behind the decline in Operating Income was an 18.9% increase in SG&A expenses.
Factors Affecting Performance
【Revenue】Revenue was ¥856.5B, an increase of +4.7% YoY. By segment, the Life Science Business grew significantly to ¥146.9B (+61.5%, 17.2% of total revenue), while Advanced Electronic Materials also contributed to revenue growth at ¥223.0B (+5.0%, 26.0% of total revenue). In contrast, Chemicals declined to ¥246.9B (-10.1%, 28.8% of total revenue), the Environmental Business decreased to ¥10.9B (-26.0%), and Cement was essentially flat at ¥160.5B (-0.2%). The primary driver of revenue growth was the expansion of the Life Science Business, while softening demand and pricing in Chemicals constrained overall growth.
【Profit and Loss】The gross margin improved to 35.0% from 34.2% in the previous year, an improvement of +0.8pt. However, the SG&A ratio rose to 27.9% from 24.6%, an increase of +3.3pt, causing the Operating Income margin to decline by -2.5pt to 7.1% (9.6% in the previous year). The increase in SG&A expenses (+18.9%) substantially exceeded the revenue growth rate (+4.7%), becoming a factor behind the decline in Operating Income. Non-operating income and expenses were net positive, including dividend income of ¥5.5B, equity in earnings of affiliates of ¥4.6B, and foreign exchange gains of ¥2.5B, narrowing the decline in Ordinary Income to ¥67.1B (-11.8%), compared with the decline in Operating Income. Extraordinary income of ¥7.0B, primarily comprising gains on the sale of investment securities of ¥6.4B, was recorded as a temporary factor. Profit before taxes was ¥73.2B (-4.6%), and after deducting income taxes and other taxes at an effective tax rate of 28.4%, Net Income attributable to owners of the parent was ¥52.0B (+6.0%). The overall picture was higher revenue but lower profit at the operating and ordinary income levels, while final profit increased due to the boost from extraordinary income; core profitability deteriorated from the previous year.
Segment Analysis
By segment, Advanced Electronic Materials (Operating Income of ¥31.3B, +10.8%, margin of 14.0%) and Life Science (Operating Income of ¥26.4B, +54.8%, margin of 18.0%) drove consolidated earnings as highly profitable segments. Cement remained stable at ¥25.5B (+1.4%, margin of 15.9%). In contrast, Chemicals fell sharply to ¥5.2B (-81.4%, margin of 2.1%), while the Environmental Business slipped into a loss of ¥-0.1B. The deterioration in profitability at both segments weighed on consolidated Operating Income. In the Life Science Business, the accounting treatment of goodwill related to Tokuyama Life Science Co., Ltd. (formerly JSR-01), acquired in October 2025, was finalized in Q1, reducing the goodwill balance. Differences in profit margins among segments have widened, and without an improvement in Chemicals’ profitability, the company’s overall business mix will become increasingly dependent on the two highly profitable segments.
Key Financial Metrics
【Profitability】The Operating Income margin was 7.1%, down -2.5pt from 9.6% in the previous year, while the Net Income margin (based on income attributable to owners of the parent) was 6.1%, essentially unchanged from 6.0% in the previous year. EPS was ¥72.34 (¥68.27 in the previous year, +6.0%).【Cash Flow Quality】Comprehensive income was ¥75.7B, exceeding Net Income attributable to owners of the parent of ¥52.0B by ¥22.2B. The primary factors were valuation difference on securities of +¥12.6B and foreign currency translation adjustments of +¥11.0B, indicating a significant contribution from valuation-related factors.【Investment Efficiency】ROE was 1.7%, with the low total asset turnover ratio acting as a bottleneck.【Financial Soundness】The Equity Ratio was 52.2%, essentially unchanged from 52.3% in the previous year. The current ratio of 173.8% and quick ratio of 149.4% indicate strong short-term liquidity resilience.
Cash Flow Analysis
Because cash flow statement data has not been disclosed, fund movements are analyzed based on changes in the balance sheet. Cash and deposits were ¥490.3B, an increase of +¥18.4B from ¥471.9B in the previous year. Trade receivables (the total of notes and accounts receivable) were ¥668.8B, down -¥89.9B from ¥758.7B in the previous year, while electronically recorded monetary claims increased by +¥17.4B, suggesting that some substitution among settlement methods may have progressed. Inventories were ¥302.8B, an increase of +¥39.8B (+15.1%) from ¥263.0B in the previous year, with notable accumulation of raw materials and work-in-process. Accounts payable were ¥495.4B, up +¥72.2B (+17.1%) from ¥423.2B in the previous year, indicating increased procurement activity. Construction in progress was ¥180.3B, down -¥120.1B (-40.0%) from ¥300.4B in the previous year, suggesting progress in transferring investment projects to property, plant and equipment. The increase in inventories and decrease in trade receivables offset each other, and changes in working capital are considered limited.
Quality of Earnings
The recurring source of earnings is core Operating Income of ¥60.8B, while extraordinary income of ¥7.0B, primarily comprising gains on the sale of investment securities of ¥6.4B, is a temporary factor and accounts for approximately 13.5% of Net Income attributable to owners of the parent of ¥52.0B. Non-operating income of ¥26.6B was only 3.1% of revenue and cannot be considered excessive dependence; however, foreign exchange gains of ¥2.5B are subject to fluctuations in market conditions. Comprehensive income was ¥75.7B, exceeding Net Income by ¥22.2B. Since the primary causes of this gap were increases in valuation difference on securities and foreign currency translation adjustments, this does not necessarily indicate an improvement in cash-generation capacity from business activities. Overall, core profitability declined from the previous year, and attention should be paid to the fact that the increase in final profit was supported by temporary extraordinary income and valuation-related factors in comprehensive income.
Earnings Forecast and Guidance
Q1 progress against the full-year plan was 21.9% for revenue (¥3,920.0B plan), 17.9% for Operating Income (¥340.0B plan), 19.7% for Ordinary Income (¥340.0B plan), and 20.0% for Net Income (¥260.0B plan). All metrics were below the 25% benchmark for simple progress, with the delay in Operating Income particularly pronounced. Against full-year expectations for revenue growth of +12.2%, the plan projects declines of -8.2% in Operating Income and -11.0% in Ordinary Income. Q1 results (revenue +4.7%, Operating Income -22.9%) show a larger decline in profit, making the pace of recovery toward the second half of the year critical to achieving the plan.
Shareholder Returns
The full-year dividend forecast is ¥60 per share, unchanged from the previous year’s actual dividend of ¥60. Based on forecast EPS of ¥361.38, the Payout Ratio is approximately 16.6%, remaining at a low level. Given the financial foundation of an Equity Ratio of 52.2% and a current ratio of 173.8%, the stability of funds available for dividends is considered favorable.
Risk Factors
-
Deterioration in Chemicals segment profitability: Against revenue of ¥246.9B (-10.1%), Operating Income fell sharply to ¥5.2B (-81.4%), with the margin declining to 2.1% (approximately 10.2% in the previous year). The contribution of Chemicals to consolidated Operating Income has contracted substantially, making the segment’s profitability trends a key point for monitoring consolidated performance.
-
Margin compression due to higher SG&A expenses: The SG&A ratio rose to 27.9% from 24.6% in the previous year, an increase of +3.3pt, while the growth rate (+18.9%) substantially exceeded the revenue growth rate (+4.7%). The improvement in the gross margin (+0.8pt) was offset by higher SG&A expenses, requiring assessment of whether the cost increase represents upfront investment or a structural increase in costs.
-
Dependence on temporary gains and valuation-related items: Extraordinary income of ¥7.0B (including gains on the sale of investment securities of ¥6.4B) accounts for approximately 13.5% of Net Income attributable to owners of the parent. The ¥22.2B gap between Comprehensive Income and Net Income is also primarily attributable to market-linked items such as valuation difference on securities and foreign currency translation adjustments.
Industry Benchmark (Reference; Compiled by the Company)
Industry Benchmark (manufacturing)
Profitability and Return
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Income Margin | 7.1% | 8.8% (4.4%–14.3%) | −1.7pt |
| Net Income Margin | 6.1% | 7.3% (3.3%–10.6%) | −1.1pt |
Both the company’s Operating Income margin and Net Income margin are below the industry median, placing profitability relatively low within the industry.
Growth and Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth Rate (YoY) | 4.7% | 6.6% (-0.3%–14.8%) | −1.9pt |
The revenue growth rate is also below the industry median but exceeds the lower bound of the IQR, leaving growth at a mid-range level within the industry.
※Source: Compiled by the Company
Key Points from the Earnings Results
-
The primary factor behind the decline in Operating Income was the 18.9% increase in SG&A expenses, substantially exceeding the revenue growth rate (+4.7%). The gross margin improved by +0.8pt, making whether the increase in expenses is temporary or structural a key consideration in assessing the future recovery of the Operating Income margin.
-
The segment mix is becoming increasingly dependent on the two highly profitable segments, Advanced Electronic Materials and Life Science (margins of 14.0% and 18.0%, respectively). The deterioration in Chemicals’ profitability (margin of 2.1%) is reflected in a shift in the composition of consolidated earnings.
-
Q1 progress against the full-year plan, including 17.9% for Operating Income, was below the standard benchmark of 25%. As the full-year plan itself anticipates higher revenue but lower profit, the pace of recovery toward the second half of the year will be an important factor in assessing achievement of the plan.
Theoretical Share Price (Reference Value)
This is a mechanically calculated reference range based solely on publicly disclosed data using a residual income model (Ohlson-type model with an explicit five-year fade). It is not a forecast of the market share price or a recommendation of any specific investment action.
| Scenario | Theoretical Share Price |
|---|---|
| bear (bearish) | ¥3,958 |
| base (base case) | ¥4,058 |
| bull (bullish) | ¥4,138 |
| Calculation Assumption | Value |
|---|---|
| Book Value per Share (BPS) | ¥3,989 |
| Adjusted Forecast EPS | ¥388.4 |
| Cost of Equity r | 9.15% (10-year Japanese government bond 2.65% + equity risk premium 6.00% + size premium 0.50%) |
| Residual Income Persistence Factor ω / Explicit Forecast Period | 0.62 / 5 years |
| Assumed Payout Ratio | 16.6% |
| Forecast EPS Confidence Adjustment | ×1.075 (based on the industry’s historical guidance achievement rate) |
| Implied PBR / PER | 1.02x / 10.4x |
Sensitivity: ¥3,941–¥4,179 at ±1% for the cost of equity, and ¥4,056–¥4,060 at ±0.1 for ω.
Note:
- Net assets as of the quarter-end are used (there is a timing gap relative to the full-year forecast).
(Calculation model: Residual Income Model / Interest Rate Reference Month: 2026-06 / This figure does not predict or guarantee the future share price)
This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. Industry benchmarks are reference information compiled by the company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting a professional as necessary.
---End of Report---
AI Financial Analysis
Executive Summary
Tokuyama’s FY2027 Q1 result was mixed: revenue growth and a substantially expanded Life Science business supported profit attributable to owners, but core operating profitability weakened materially. Revenue rose 4.7% year on year to ¥85.7bn. Gross profit increased 7.0% to ¥30.0bn, lifting the gross margin by approximately 80bp to 35.0%. However, SG&A expenses rose 18.9% to ¥23.9bn, materially outpacing revenue growth. Consequently, operating income fell 22.9% to ¥6.1bn. The operating margin compressed by approximately 250bp, to 7.1% from 9.6% a year earlier. Ordinary income declined 11.8% to ¥6.7bn, although it exceeded operating income because non-operating income included ¥0.5bn of dividend income, ¥0.5bn of equity-method income and ¥0.3bn of FX gains. Profit attributable to owners increased 6.0% to ¥5.2bn and EPS rose to ¥72.34. Net income growth did not reflect an improvement in the underlying operating trend, as extraordinary gains included a ¥6.4bn gain on sales of investment securities. Net extraordinary income of ¥0.6bn represented about 11.8% of profit attributable to owners, providing a meaningful but not dominant uplift. The effective tax rate declined to 28.4% from the prior-year quarter’s higher tax burden, which also supported bottom-line growth. Electronic Advanced Materials and Life Science were the principal positive segment contributors, while Chemicals saw a sharp profit contraction and Environmental moved to a small loss. Life Science revenue grew 61.4% year on year, reflecting the consolidation-related expansion following the acquisition of Tokuyama Life Science. The balance sheet remains sound, with a 173.8% current ratio, 149.4% quick ratio, 0.91x debt-to-equity ratio and 12.08x interest coverage. Nevertheless, the disclosed annualized 71-day DSO, 132-day DIO and 122-day cash-conversion cycle indicate that working-capital intensity is a key operational issue. Full-year guidance implies a back-end-loaded recovery, as Q1 operating-income progress was only 17.9% against the normal 25% seasonal benchmark. The central forward implication is that Tokuyama must convert revenue growth into operating leverage, particularly by stabilizing Chemicals and controlling post-acquisition and research-related overhead.
Profitability Analysis
Annualized DuPont ROE was 6.9%, decomposed into a 6.1% net profit margin, 0.593x asset turnover and 1.91x financial leverage. This places the principal constraint on shareholder returns in operating profitability and asset efficiency rather than excessive leverage. The annualized net margin was preserved at a reasonable level despite the decline in operating income, but this reflected non-operating income, lower tax burden and securities-sale gains rather than stronger core earnings. Gross margin improved to 35.0% from approximately 34.2%, indicating that production and pricing economics were not uniformly weak. The largest adverse change was SG&A intensity: SG&A increased 18.9% while revenue grew 4.7%, raising the SG&A-to-sales ratio to 27.9% from 24.6%. This increase more than absorbed the gross-margin improvement, causing the operating margin to decline to 7.1% from 9.6%. The 5-factor DuPont tax burden was 0.711, consistent with a normal effective tax rate, while the interest burden was above 1.0 because profit before tax benefited from net non-operating and extraordinary income. Interest coverage remained robust at 12.08x, so interest expense of ¥0.5bn is not currently the main earnings constraint. Chemicals was the main drag, with revenue down 10.1% to ¥24.7bn and segment profit down 81.4% to ¥0.5bn; its segment margin fell to 2.1% from 10.2%. By contrast, Electronic Advanced Materials delivered revenue growth of 5.0% to ¥22.0bn and segment-profit growth of 10.8% to ¥3.1bn, with a segment margin of 14.2%. Cement remained stable, with revenue up 1.4% to ¥16.0bn and segment profit up 1.4% to ¥2.6bn, equivalent to a 15.9% segment margin. Life Science generated the fastest growth, with revenue up 61.4% to ¥14.7bn and segment profit up 54.8% to ¥2.6bn; its 18.0% segment margin is the highest among reported operating segments. The core business by operating-income contribution was Electronic Advanced Materials at ¥3.1bn, ahead of Cement and Life Science. Sustainability of the reported net-profit growth therefore depends on the durability of Electronics and Life Science earnings and on whether Chemicals can recover, rather than on financial leverage or one-off gains.
Growth Assessment
Revenue growth was broad enough to offset the decline in Chemicals, but its composition has shifted toward Life Science following the acquisition and toward Electronic Advanced Materials. Electronic Advanced Materials appears to offer the strongest organic earnings momentum, combining 5.0% revenue growth with 10.8% profit growth. Life Science added ¥5.6bn of revenue and roughly ¥0.9bn of segment profit year on year, but the acquisition-related expansion makes comparability with the prior period less direct. Cement was resilient but broadly flat, suggesting it is a stabilizer rather than the principal growth engine. Chemicals requires close monitoring because its ¥22.9bn year-on-year reduction in segment profit accounted for most of the consolidated segment-profit decline. Environmental revenue declined 26.9% to ¥1.1bn and segment profit shifted from a ¥0.2bn profit to a marginal loss. Full-year company guidance calls for revenue of ¥392.0bn, up 12.2%, operating income of ¥34.0bn, down 8.2%, and profit attributable to owners of ¥26.0bn. Q1 revenue progress was 21.9%, 3.1 percentage points below the standard 25% progress rate. Q1 operating-income progress was 17.9%, 7.1 percentage points below the standard rate, while ordinary-income progress was 19.7%, 5.3 points below. Q1 attributable-profit progress was 20.0%, also 5.0 points below the standard rate. These progress rates point to a need for a significant second-half earnings recovery, consistent with management’s revised full-year outlook. Guidance itself anticipates that revenue growth will not fully translate into operating-profit growth, reinforcing the importance of mix, input costs and SG&A discipline.
Financial Health
Liquidity is healthy, with current assets of ¥215.8bn against current liabilities of ¥124.2bn, producing a current ratio of 173.8% and working capital of ¥91.7bn. The 149.4% quick ratio indicates that short-term obligations can be covered without reliance on inventory liquidation. Cash and deposits of ¥49.0bn were 7.83x short-term loans of ¥6.3bn. Short-term debt accounted for only 6.3% of interest-bearing debt, limiting near-term refinancing and maturity-mismatch risk. Interest-bearing debt totaled ¥99.5bn, consisting principally of ¥93.2bn in long-term loans, ¥25.0bn in bonds and ¥19.0bn in commercial paper, including current portions where applicable. Debt-to-equity was 0.91x and debt-to-capital was 24.8%, both consistent with a manageable capital structure and well below aggressive-leverage thresholds. Total equity increased ¥4.1bn year on year to ¥302.0bn, while total assets increased ¥8.3bn to ¥577.9bn. Long-term loans increased modestly by ¥0.8bn, while total cash increased ¥1.8bn. Goodwill of ¥30.6bn equaled 10.1% of equity and 5.3% of total assets, indicating that balance-sheet value is not excessively dependent on acquired goodwill. Intangible assets were 13.0% of assets, a moderate level for a company expanding in Life Science. The acquisition accounting for Tokuyama Life Science was finalized during the quarter, reducing goodwill in the Life Science segment; this lowers goodwill exposure modestly. Asset-retirement obligations were ¥0.3bn, immaterial relative to total liabilities and not indicative of a significant disclosed environmental-liability burden.
Notable B/S Changes
Construction in progress: -¥12.0bn (-40.0%) to ¥18.0bn — a substantial reduction suggests completion, transfer or normalization of the investment pipeline; the use of the released capacity and associated return on capital should be monitored. Finished goods: +¥4.0bn (+15.1%) to ¥30.3bn — finished-goods accumulation contributes to the elevated disclosed annualized inventory days and increases demand-normalization risk. Accounts payable: +¥7.2bn (+17.0%) to ¥49.5bn — higher supplier financing partly supports working capital, but its sustainability depends on supplier terms and purchasing activity. Accounts receivable: -¥9.0bn (-12.0%) to ¥66.2bn — trade receivables declined, although broader collection efficiency remains an issue given the disclosed 71-day annualized DSO. Investment securities: +¥2.1bn (+3.6%) to ¥61.0bn — the portfolio remains significant at 10.5% of total assets, and Q1 earnings included a ¥6.4bn securities-sale gain. Goodwill: -¥0.4bn (-1.3%) to ¥30.6bn — the decline followed finalization of acquisition accounting for Tokuyama Life Science, modestly reducing M&A-related balance-sheet exposure.
Cash Flow Quality
Working-capital efficiency is the principal disclosed cash-conversion concern. Annualized DSO was 71 days, above the 60-day warning threshold, indicating relatively slow customer collections for a manufacturing group. Annualized DIO was 132 days, above the 90-day warning threshold, indicating elevated capital tied up in inventory. The annualized cash-conversion cycle was 122 days, marginally above the 120-day warning threshold and therefore represents a material operational risk. Trade receivables declined by ¥9.0bn year on year to ¥66.2bn, but electronically recorded monetary claims increased by ¥1.7bn to ¥8.6bn, so collection efficiency should be assessed on the broader receivables base. Trade payables increased ¥7.2bn to ¥49.5bn, providing some supplier-financing support to working capital. Finished goods increased ¥4.0bn year on year to ¥30.3bn, while raw materials increased ¥1.2bn to ¥26.4bn and work in process increased ¥1.2bn to ¥24.1bn. The simultaneous rise in finished goods and WIP warrants attention because it may reflect slower downstream demand absorption, longer production cycles, or deliberate inventory positioning. For a chemical and materials manufacturer, elevated inventories also increase exposure to demand volatility, product mix changes and potential valuation pressure. The reported profit attributable to owners includes a ¥6.4bn gain on sale of investment securities, so cash-flow conversion should be judged primarily against recurring operating earnings rather than reported net income.
Dividend Sustainability
The full-year dividend forecast is ¥132 per share. Against forecast EPS of ¥361.38, the implied dividend payout ratio is approximately 36.5%. This is below the 60% sustainability benchmark and leaves a meaningful earnings retention buffer. The forecast dividend is also supported by a capital structure with 0.91x debt-to-equity, 24.8% debt-to-capital and strong liquidity ratios. However, dividend resilience is linked to the delivery of the ¥26.0bn full-year attributable-profit forecast, for which Q1 progress was 20.0%. The company revised both its earnings and dividend forecast on July 29, 2026, making execution against the revised plan the key near-term determinant of payout capacity. The moderate payout ratio provides flexibility to absorb earnings volatility in Chemicals or higher working-capital requirements. The absence of a disclosed share-buyback amount means the analysis is limited to the dividend payout ratio rather than a total return ratio.
Risk Assessment
Business risks include High priority — Chemicals: revenue fell 10.1% and segment profit fell 81.4% to ¥0.5bn, leaving the segment with a 2.1% margin. Persistent pricing pressure, energy and feedstock-cost volatility, or weak industrial demand could continue to depress consolidated operating profit., High priority — Working-capital intensity: disclosed annualized DSO of 71 days, DIO of 132 days and a 122-day cash-conversion cycle raise the risk that inventory and receivables absorb cash during a period of lower operating income., Medium-high priority — Life Science integration: revenue and profit grew 61.4% and 54.8%, respectively, following acquisition-related expansion. The growth contribution increases integration, customer-retention and synergy-realization risk., Medium priority — Electronic-materials cyclicality: Electronic Advanced Materials is the core business by segment profit and generated a 14.2% segment margin. Its increased importance heightens exposure to semiconductor and electronics demand cycles., Medium priority — Chemical manufacturing inputs and regulation: the group remains exposed to electricity, fuel and raw-material price swings, environmental compliance requirements, production disruptions and product-quality risk..
Financial risks include Medium priority — Earnings normalization: ¥0.6bn of net extraordinary income, mainly a ¥6.4bn investment-securities gain, supported reported attributable profit and is not a recurring substitute for operating-income recovery., Medium priority — Interest-rate exposure: interest expense increased to ¥0.5bn from ¥0.3bn year on year. Coverage remains strong at 12.08x, but the ¥99.5bn interest-bearing debt balance creates sensitivity to sustained funding-cost increases., Low-medium priority — Intangible-value risk: goodwill is modest at 10.1% of equity, but Life Science acquisition performance remains relevant to preserving acquired intangible and goodwill value..
Key concerns include ROIC of 4.9% is below the 5% alert threshold. This indicates that returns on invested capital are currently weak for a capital-intensive materials manufacturer and makes disciplined capital allocation critical., SG&A rose 18.9%, materially faster than 4.7% revenue growth. Unless this reflects scalable strategic investment, it risks continued operating-margin compression., Full-year operating-income guidance requires a substantial improvement after Q1 achieved only 17.9% of the annual target., Finished goods, raw materials and WIP all increased year on year, which should be monitored alongside order conditions and production utilization..
Investment Implications
Key takeaways include Revenue growth, gross-margin expansion and strong Electronic Advanced Materials and Life Science results demonstrate that parts of the portfolio retain attractive earnings capacity., The 250bp operating-margin contraction and Chemicals profit collapse show that consolidated revenue growth is not yet translating into operating leverage., The balance sheet provides resilience: liquidity is strong, debt metrics are conservative and interest coverage remains robust., Reported Q1 attributable-profit growth overstates recurring momentum because of investment-securities gains and a more favorable tax burden., Working-capital efficiency and ROIC are the most important financial operating issues to resolve..
Metrics to watch include Chemicals segment revenue, segment margin and recovery in segment profit from ¥0.5bn, Electronic Advanced Materials order conditions, revenue growth and margin sustainability, Life Science post-acquisition revenue retention, segment margin and goodwill trend, Annualized DSO, DIO and cash-conversion cycle, SG&A growth relative to revenue growth and consolidated operating-margin trajectory, Progress toward ¥34.0bn full-year operating-income guidance, ROIC improvement from 4.9%, Interest expense and long-term borrowing levels.
Regarding relative positioning, Tokuyama combines a conservatively financed balance sheet with a diversified materials portfolio and high-margin Electronics and Life Science operations. Relative to the stated profitability benchmarks, however, its 7.1% operating margin is below the 8% threshold for a good rating, annualized ROE of 6.9% is below the 8% concern threshold, and ROIC of 4.9% is weak. Its financial positioning is stronger than its present operating-efficiency positioning.